vs
Consensus Cloud Solutions, Inc.（CCSI）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Consensus Cloud Solutions, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.2倍（$87.1M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 23.5%，领先360.5%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 0.1%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -0.6%）
Consensus Cloud Solutions是一家云解决方案提供商，核心产品包括加密数字传真、安全文档交换、工作流程自动化工具，主要面向医疗、法律、金融服务等领域的北美企业客户提供相关服务。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CCSI vs RIGL — 直观对比
营收规模更大
CCSI
是对方的1.2倍
$69.8M
营收增速更快
RIGL
高出21.1%
0.1%
净利率更高
RIGL
高出360.5%
23.5%
两年增速更快
RIGL
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $87.1M | $69.8M |
| 净利润 | $20.5M | $268.1M |
| 毛利率 | 80.0% | 91.5% |
| 营业利润率 | 41.1% | 33.2% |
| 净利率 | 23.5% | 384.0% |
| 营收同比 | 0.1% | 21.2% |
| 净利润同比 | 13.5% | 1769.2% |
| 每股收益（稀释后） | $1.06 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCSIRIGL
| Q4 25 | $87.1M | $69.8M | ||
| Q3 25 | $87.8M | $69.5M | ||
| Q2 25 | $87.7M | $101.7M | ||
| Q1 25 | $87.1M | $53.3M | ||
| Q4 24 | $87.0M | $57.6M | ||
| Q3 24 | $87.8M | $55.3M | ||
| Q2 24 | $87.5M | $36.8M | ||
| Q1 24 | $88.1M | $29.5M |
净利润CCSIRIGL
| Q4 25 | $20.5M | $268.1M | ||
| Q3 25 | $22.1M | $27.9M | ||
| Q2 25 | $20.8M | $59.6M | ||
| Q1 25 | $21.2M | $11.4M | ||
| Q4 24 | $18.1M | $14.3M | ||
| Q3 24 | $21.1M | $12.4M | ||
| Q2 24 | $23.9M | $-1.0M | ||
| Q1 24 | $26.4M | $-8.2M |
毛利率CCSIRIGL
| Q4 25 | 80.0% | 91.5% | ||
| Q3 25 | 80.0% | 93.2% | ||
| Q2 25 | 79.9% | 95.6% | ||
| Q1 25 | 79.3% | 91.7% | ||
| Q4 24 | 79.5% | 89.9% | ||
| Q3 24 | 79.9% | 85.5% | ||
| Q2 24 | 80.4% | 92.4% | ||
| Q1 24 | 80.7% | 93.1% |
营业利润率CCSIRIGL
| Q4 25 | 41.1% | 33.2% | ||
| Q3 25 | 43.2% | 40.9% | ||
| Q2 25 | 44.5% | 60.1% | ||
| Q1 25 | 43.0% | 23.9% | ||
| Q4 24 | 38.4% | 28.9% | ||
| Q3 24 | 43.8% | 25.4% | ||
| Q2 24 | 45.6% | 1.2% | ||
| Q1 24 | 42.7% | -23.6% |
净利率CCSIRIGL
| Q4 25 | 23.5% | 384.0% | ||
| Q3 25 | 25.2% | 40.2% | ||
| Q2 25 | 23.7% | 58.6% | ||
| Q1 25 | 24.3% | 21.5% | ||
| Q4 24 | 20.8% | 24.9% | ||
| Q3 24 | 24.1% | 22.5% | ||
| Q2 24 | 27.3% | -2.8% | ||
| Q1 24 | 29.9% | -27.9% |
每股收益（稀释后）CCSIRIGL
| Q4 25 | $1.06 | $14.11 | ||
| Q3 25 | $1.15 | $1.46 | ||
| Q2 25 | $1.07 | $3.28 | ||
| Q1 25 | $1.07 | $0.63 | ||
| Q4 24 | $0.92 | $0.82 | ||
| Q3 24 | $1.09 | $0.70 | ||
| Q2 24 | $1.24 | $-0.06 | ||
| Q1 24 | $1.37 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.7M | $155.0M |
| 总债务越低越好 | $558.4M | $52.5M |
| 股东权益账面价值 | $13.8M | $391.5M |
| 总资产 | $663.8M | $513.6M |
| 负债/权益比越低杠杆越低 | 40.54× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CCSIRIGL
| Q4 25 | $74.7M | $155.0M | ||
| Q3 25 | $97.6M | $137.1M | ||
| Q2 25 | $57.9M | $108.4M | ||
| Q1 25 | $53.4M | $77.1M | ||
| Q4 24 | $33.5M | $77.3M | ||
| Q3 24 | $54.6M | $61.1M | ||
| Q2 24 | $49.2M | $49.1M | ||
| Q1 24 | $61.5M | $49.5M |
总债务CCSIRIGL
| Q4 25 | $558.4M | $52.5M | ||
| Q3 25 | $578.6M | $60.0M | ||
| Q2 25 | $578.2M | $60.0M | ||
| Q1 25 | $583.7M | $60.0M | ||
| Q4 24 | $593.0M | $60.0M | ||
| Q3 24 | $612.5M | $60.0M | ||
| Q2 24 | $642.8M | $60.0M | ||
| Q1 24 | $671.7M | $60.0M |
股东权益CCSIRIGL
| Q4 25 | $13.8M | $391.5M | ||
| Q3 25 | $-2.6M | $117.6M | ||
| Q2 25 | $-26.5M | $81.9M | ||
| Q1 25 | $-49.4M | $18.6M | ||
| Q4 24 | $-79.5M | $3.3M | ||
| Q3 24 | $-93.2M | $-14.6M | ||
| Q2 24 | $-124.4M | $-29.9M | ||
| Q1 24 | $-151.8M | $-31.7M |
总资产CCSIRIGL
| Q4 25 | $663.8M | $513.6M | ||
| Q3 25 | $675.0M | $242.5M | ||
| Q2 25 | $641.5M | $206.7M | ||
| Q1 25 | $629.6M | $176.0M | ||
| Q4 24 | $602.2M | $164.0M | ||
| Q3 24 | $622.5M | $139.4M | ||
| Q2 24 | $608.5M | $128.4M | ||
| Q1 24 | $620.8M | $126.5M |
负债/权益比CCSIRIGL
| Q4 25 | 40.54× | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $7.3M | — |
| 自由现金流率自由现金流/营收 | 8.4% | — |
| 资本支出强度资本支出/营收 | 9.1% | — |
| 现金转化率经营现金流/净利润 | 0.74× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $105.9M | — |
8季度趋势，按日历期对齐
经营现金流CCSIRIGL
| Q4 25 | $15.2M | $22.0M | ||
| Q3 25 | $51.6M | $24.0M | ||
| Q2 25 | $28.3M | $30.5M | ||
| Q1 25 | $40.9M | $-893.0K | ||
| Q4 24 | $11.1M | $14.5M | ||
| Q3 24 | $41.6M | $21.7M | ||
| Q2 24 | $24.4M | $302.0K | ||
| Q1 24 | $44.7M | $-5.0M |
自由现金流CCSIRIGL
| Q4 25 | $7.3M | — | ||
| Q3 25 | $44.4M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $33.7M | — | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $33.6M | — | ||
| Q2 24 | $15.8M | — | ||
| Q1 24 | $35.8M | — |
自由现金流率CCSIRIGL
| Q4 25 | 8.4% | — | ||
| Q3 25 | 50.6% | — | ||
| Q2 25 | 23.2% | — | ||
| Q1 25 | 38.7% | — | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 18.1% | — | ||
| Q1 24 | 40.6% | — |
资本支出强度CCSIRIGL
| Q4 25 | 9.1% | — | ||
| Q3 25 | 8.2% | — | ||
| Q2 25 | 9.1% | — | ||
| Q1 25 | 8.3% | — | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 9.1% | — | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 10.1% | — |
现金转化率CCSIRIGL
| Q4 25 | 0.74× | 0.08× | ||
| Q3 25 | 2.34× | 0.86× | ||
| Q2 25 | 1.36× | 0.51× | ||
| Q1 25 | 1.94× | -0.08× | ||
| Q4 24 | 0.62× | 1.01× | ||
| Q3 24 | 1.97× | 1.75× | ||
| Q2 24 | 1.02× | — | ||
| Q1 24 | 1.69× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
